A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci
Pneucast
1 other identifier
observational
450
1 country
3
Brief Summary
A study taking swabs from the back of the nose (nasopharynx) to look at carriage of pneumococci.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2008
Typical duration for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 28, 2009
CompletedFirst Posted
Study publicly available on registry
December 29, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedMarch 22, 2019
September 1, 2010
2.2 years
December 28, 2009
March 20, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Presence of pneumococci in nasopharyngeal swabs
Eligibility Criteria
Community samples taken within the home of eligible subjects.
You may qualify if:
- Born in a cohort eligible for routine or catch up pneumococcal conjugate vaccination (i.e. date of birth since 4th September 2004) or a family member where a child is eligible and has been enrolled
- Written informed consent given by the subject's parent/ legal guardian as well as assent from the child after the nature of the study has been explained to them or
- Written informed consent given by the subject after the nature of the study has been explained to them
You may not qualify if:
- Moderate to severe disability.
- Cerebral palsy, syndromes and neurological disorders affecting swallowing.
- Ear Nose and Throat disorders affecting the anatomy of the ear,i.e.malformed ears.
- Confirmed or suspected immunodeficiency (congenital or acquired).
- On immunosuppressive therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Health Protection Agency
Stevenage, Hertfordshire, United Kingdom
Health Protection Agency
Gloucester, United Kingdom
Health Protection Agency
London, NW9 5HT, United Kingdom
Related Publications (1)
van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014 Jul 23;32(34):4349-55. doi: 10.1016/j.vaccine.2014.03.017. Epub 2014 Mar 21.
PMID: 24657717RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
December 28, 2009
First Posted
December 29, 2009
Study Start
January 1, 2008
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
March 22, 2019
Record last verified: 2010-09